some issues with sarcoidosis return; neuropathy in feet; coughing a lot; enlarged liver; few patches of psoriasis developed on face and scalp; vaccine injuries; This spontaneous case was reported by a consumer and describes the occurrence of SARCOIDOSIS (some issues with sarcoidosis return) and NEUROPATHY PERIPHERAL (neuropathy in feet) in a 56-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Psoriatic arthritis and Plaque psoriasis.    Concurrent medical conditions included Psoriatic arthritis and Plaque psoriasis (Moderate to Severe).   On 15-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. In 2022, the patient experienced SARCOIDOSIS (some issues with sarcoidosis return) (seriousness criterion medically significant), NEUROPATHY PERIPHERAL (neuropathy in feet) (seriousness criterion medically significant), COUGH (coughing a lot), HEPATOMEGALY (enlarged liver), PSORIASIS (few patches of psoriasis developed on face and scalp) and VACCINATION SITE INJURY (vaccine injuries). At the time of the report, SARCOIDOSIS (some issues with sarcoidosis return) and PSORIASIS (few patches of psoriasis developed on face and scalp) had not resolved, NEUROPATHY PERIPHERAL (neuropathy in feet), HEPATOMEGALY (enlarged liver) and VACCINATION SITE INJURY (vaccine injuries) had resolved and COUGH (coughing a lot) outcome was unknown.            No concomitant medication information provided. No treatment information provided.  The reporter's causality for the events of coughing a lot, enlarged liver, few patches of psoriasis developed on face and scalp, neuropathy in feet and some issues with sarcoidosis return with Adalimumab Solution for Injection was Not Provided.    Company comment: This is a spontaneous case concerning a 56-year-old male patient with reported medical history of psoriatic arthritis, who experienced the unexpected serious (medically significant) events of sarcoidosis and neuropathy peripheral among other non-serious events. The events occurred on unknown day after the second dose of mRNA-1273 vaccine. No information disclosed about diagnostic tests performed or treatments received. Patient`s concomitant medication  Adalimumab could be considered as a confounder in this case. At the time of the report, event sarcoidosis was not resolved and neuropathy peripheral was resolved. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Reporter's Comments: This is a spontaneous case concerning a 56-year-old male patient with reported medical history of psoriatic arthritis, who experienced the unexpected serious (medically significant) events of sarcoidosis and neuropathy peripheral among other non-serious events. The events occurred on unknown day after the second dose of mRNA-1273 vaccine. No information disclosed about diagnostic tests performed or treatments received. Patient`s concomitant medication  Adalimumab could be considered as a confounder in this case. At the time of the report, event sarcoidosis was not resolved and neuropathy peripheral was resolved. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.